Document is current
Any future updates will be listed below
-
Authors
Omura, Satoshi N. https://orcid.org/0000-0003-2436-0847
Nakagawa, Ryoya
Kajimoto, Shohei
Okazaki, Sae
Ishiguro, Soh https://orcid.org/0000-0002-2826-2470
Mori, Hideto https://orcid.org/0000-0003-4849-0056
Onishi, Kosuke https://orcid.org/0009-0009-3256-5819
Kashiwakura, Yuji https://orcid.org/0000-0003-0585-3937
Hiramoto, Takafumi https://orcid.org/0000-0003-4054-6748
Horinaka, Kio
Tanaka, Mamoru
Hirano, Hisato
Jividen, Kasey
Yamashita, Keitaro https://orcid.org/0000-0002-5442-7582
Tsai, Shengdar Q. https://orcid.org/0000-0001-9161-3993
Yachie, Nozomu
Ohmori, Tsukasa https://orcid.org/0000-0001-5082-6394
Nishimasu, Hiroshi https://orcid.org/0000-0002-2505-1416
Nureki, Osamu https://orcid.org/0000-0003-1813-7008
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP25ama121012)
- License Information
-
More Information
Article History
Received: 14 September 2025
Accepted: 23 March 2026
First Online: 16 April 2026
Competing interests
: The University of Tokyo and MODALIS Corporation have filed a patent application related to this work. The inventors are Osamu Nureki, Hiroshi Nishimasu, Shohei Kajimoto, and Hisato Hirano. The patent application pertains to modified Cas9 proteins and their use for genome editing (application number JP2018/032948, published as WO2019/049913). The remaining authors declare no competing interests.
